These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32194562)

  • 1. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
    Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
    Front Immunol; 2020; 11():344. PubMed ID: 32194562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
    Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J
    Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.
    Scholtissek B; Zahn S; Maier J; Klaeschen S; Braegelmann C; Hoelzel M; Bieber T; Barchet W; Wenzel J
    J Invest Dermatol; 2017 Jul; 137(7):1484-1492. PubMed ID: 28351661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
    Klaeschen AS; Wolf D; Brossart P; Bieber T; Wenzel J
    Exp Dermatol; 2017 Aug; 26(8):728-730. PubMed ID: 27892610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
    Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B
    Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666
    [No Abstract]   [Full Text] [Related]  

  • 6. NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus.
    Vorwerk G; Zahn S; Bieber T; Wenzel J
    Exp Dermatol; 2021 Jun; 30(6):847-852. PubMed ID: 33687107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
    Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
    Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
    JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
    Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
    J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-α stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus.
    Zahn S; Rehkämper C; Ferring-Schmitt S; Bieber T; Tüting T; Wenzel J
    Br J Dermatol; 2011 Nov; 165(5):1118-23. PubMed ID: 21711324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
    Niebel D; de Vos L; Fetter T; Brägelmann C; Wenzel J
    Am J Clin Dermatol; 2023 Jul; 24(4):521-540. PubMed ID: 37140884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.
    Wenzel J; Landmann A; Vorwerk G; Kuhn A
    Exp Dermatol; 2018 Jan; 27(1):95-97. PubMed ID: 28833566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
    Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
    PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
    Dai Z; Chen J; Chang Y; Christiano AM
    JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
    Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
    Front Immunol; 2021; 12():775353. PubMed ID: 34868043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.
    Sarkar MK; Hile GA; Tsoi LC; Xing X; Liu J; Liang Y; Berthier CC; Swindell WR; Patrick MT; Shao S; Tsou PS; Uppala R; Beamer MA; Srivastava A; Bielas SL; Harms PW; Getsios S; Elder JT; Voorhees JJ; Gudjonsson JE; Kahlenberg JM
    Ann Rheum Dis; 2018 Nov; 77(11):1653-1664. PubMed ID: 30021804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review.
    Yu C; Chang C; Zhang J
    J Autoimmun; 2013 Mar; 41():34-45. PubMed ID: 23380467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
    Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
    Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-encapsulated anandamide reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus.
    McCormick ET; Draganski A; Chalmers S; Zahn J; Garcia S; Nussbaum D; Friedman A; Putterman C; Friedman J
    Exp Dermatol; 2023 Dec; 32(12):2072-2083. PubMed ID: 37726950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies.
    Fetter T; Wenzel J
    Exp Dermatol; 2020 Nov; 29(11):1123-1132. PubMed ID: 32633821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.